US 12,097,189

Application 18/613,281 · Granted Sep 24, 2024

Pharmaceutical composition for modified release

Estimated expiration

September 28, 2029

2y 312d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Application 18437323 has not been granted a patent number
Earliest effective filing
Mar 28, 2011
+ 20 years
Mar 28, 2031
PTA +0d
Mar 28, 2031
TD cap (US 10,842,780)
Sep 28, 2029
Final
Sep 28, 2029

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
March 22, 2024
Earliest effective filing
March 28, 2011
Issue date
September 24, 2024
PTA
0 days
Base expiry (before PTA)
March 28, 2031

March 28, 2011 + 20 years = March 28, 2031

  • Continuation of application 18/437,323, filed Feb 9, 2024
  • Continuation of application 18/339,513, filed Jun 22, 2023
  • Continuation of application 17/114,890, filed Dec 8, 2020, issued as US 11,707,451
  • Continuation of application 14/584,933, filed Dec 29, 2014
  • Divisional of application 13/073,721, filed Mar 28, 2011
  • Divisional of application 13/073,721, filed Mar 28, 2011
  • Continuation of application 14/584,933, filed Dec 29, 2014
  • Divisional of application 13/073,721, filed Mar 28, 2011
  • Continuation of application 17/114,890, filed Dec 8, 2020, issued as US 11,707,451
  • Continuation of application 14/584,933, filed Dec 29, 2014
  • Divisional of application 13/073,721, filed Mar 28, 2011
  • Continuation of application 18/339,513
  • Continuation of application 17/114,890, filed Dec 8, 2020, issued as US 11,707,451
  • Continuation of application 14/584,933, filed Dec 29, 2014
  • Divisional of application 13/073,721, filed Mar 28, 2011
  • PRO61/318,569 — Provisional — not used for base term
  • PRO61/318,569 — Provisional — not used for base term
  • PRO61/318,569 — Provisional — not used for base term
  • PRO61/318,569 — Provisional — not used for base term
  • PRO61/318,569 — Provisional — not used for base term
  • PRO61/318,569 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to September 28, 2029 (earliest expiring referenced patent: US 10,842,780)

  • US 11,707,451· Application 17/114,890Capping patent

    Pharmaceutical composition for modified release

    Filing date
    Dec 8, 2020
    Earliest effective filing
    Mar 28, 2011
    Issue date
    Jul 25, 2023
    PTA
    +44 days
    Calculated expiration
    May 11, 2031

    Continuation of 14/584,933, filed Dec 29, 2014

    Divisional of 13/073,721, filed Mar 28, 2011

    Divisional of 13/073,721, filed Mar 28, 2011

    Mar 28, 2011 + 20y + 44d PTA = May 11, 2031

  • US 10,842,780· Application 15/432,854Capping patent

    Pharmaceutical composition for modified release

    Filing date
    Feb 14, 2017
    Earliest effective filing
    Sep 28, 2009
    Issue date
    Nov 24, 2020
    PTA
    0 days
    Calculated expiration
    Sep 28, 2029

    Continuation of 12/568,313, filed Sep 28, 2009

    Sep 28, 2009 + 20y = Sep 28, 2029

  • US 8,877,214· Application 13/073,677

    Pharmaceutical composition for modified release

    Filing date
    Mar 28, 2011
    Earliest effective filing
    Mar 28, 2011
    Issue date
    Nov 4, 2014
    PTA
    +43 days
    Calculated expiration
    May 10, 2031

    Mar 28, 2011 + 20y + 43d PTA = May 10, 2031

  • US 12,059,409· Application 18/613,270(from application 18/613,270)

    Pharmaceutical composition for modified release

    Filing date
    Mar 22, 2024
    Earliest effective filing
    Sep 28, 2009
    Issue date
    Aug 13, 2024
    PTA
    0 days
    Calculated expiration
    Sep 28, 2029

    Continuation of 18/448,244, filed Aug 11, 2023

    Continuation of 16/952,795, filed Nov 19, 2020

    Divisional of 15/432,854, filed Feb 14, 2017, issued as US 10,842,780

    Continuation of 12/568,313, filed Sep 28, 2009

    Continuation of 12/568,313, filed Sep 28, 2009

    Divisional of 15/432,854, filed Feb 14, 2017, issued as US 10,842,780

    Continuation of 12/568,313, filed Sep 28, 2009

    Continuation of 16/952,795, filed Nov 19, 2020

    Divisional of 15/432,854, filed Feb 14, 2017, issued as US 10,842,780

    Continuation of 12/568,313, filed Sep 28, 2009

    Sep 28, 2009 + 20y = Sep 28, 2029

  • US APP:18437323(from application 18/437,323)

    Could not resolve calculation details

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 18/613,281 · US 12,097,189

PatentReply compiles the prosecution history behind US 12,097,189: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12097189

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.